Abstract: The present invention relates to a gene sequence construct for gene therapy for HIV infection. The gene sequence construct is constructed by means of sequentially connecting, via a coding sequence of a linker polypeptide, a gene coding sequence of a variable region scFv in each light chain and heavy chain of a monoclonal antibody against antigens at different binding sites involved in the different steps of HIV infection of a human CD4+ T cell, a gene coding sequence of a variable region scFv in each light chain and heavy chain of a monoclonal antibody bound to a human CD4 receptor site, a gene coding sequence of an Fc fragment in a human IgG constant region, and a gene coding sequence of a polypeptide for inhibiting the fusion of HIV and a CD4+ T cell membrane, and by placing the connected gene coding sequences downstream of a promoter and a secretion signal peptide coding sequence, thereby expressing a single-gene-encoded secretion-type antibody-like protein molecule.

Abstract: A gene sequence construct for gene therapy of human immunodeficiency virus (HIV) infection. By sequentially linking, by means of a coding sequence of a linker polypeptide, gene coding sequences of respective single-chain variable fragment (scFv) regions of light chains and heavy chains of monoclonal antibodies having different binding site antigens involved in different steps of infecting human CD4+T cells by an HIV, gene coding sequences of respective scFv regions of light chains and heavy chains of monoclonal antibodies bound to a CD4 receptor site, and a gene coding sequence of a polypeptide for inhibiting the fusion of an HIV and a CD4+T cell membrane, a gene sequence construct is constructed in a promoter and downstream of a secretory signal peptide coding sequence to express a secretory antibody-like protein molecule coded by a single gene.

Abstract: A nucleic acid construct for AIDS gene therapy. The nucleic acid construct comprises multiple polynucleotides encoding single chain variable region fragments of an anti-AIDS neutralizing antibody, and a polynucleotide encoding an immunoglobulin Fc fragment; the single chain variable region fragments of the anti-AIDS neutralizing antibody comprise a single chain variable region fragment capable of specifically binding to HIV, and a single chain variable region fragment capable of specifically binding to a CD4 receptor. The construct can be used for gene therapy of AIDS caused by HIV infection, and the construct can be used for expressing a bispecific/polyspecific neutralizing antibody having broad-spectrum and high-efficiency neutralizing activity in vitro and in vivo and can be used for clinical research and new drug development of AIDS gene therapy drugs delivered by recombinant viral or non-viral vectors.

Abstract: Disclosed herein are gene therapy vectors used for efficiently transducing cells to express a human ?-globin gene. Specifically disclosed is an expression vector which comprises: an expression cassette for a ?-globin gene, which comprises exons and introns of human ?-globin gene, as well as cis-acting elements including one or more of WPRE, SV40 polyadenylation signal and/or SV40 ori. The disclosed expression vectors have significantly enhanced viral vector packaging efficiency in viral vector packaging cell lines, which leads to effective integration of lentiviral vectors and high expression level of ?-globin gene in target cells. Also disclosed are pharmaceutical compositions and therapeutic methods utilizing such expression vectors.

Abstract: A nucleic acid construct for improving an adeno-associated virus yield, and a construction method therefor. The nucleic acid construct includes: an adeno-associated virus (AAV) element, and a polynucleotide encoding an IE protein. Said AAV element includes a polynucleotide encoding a Cap protein, a polynucleotide encoding a Rep protein, and an AAV cis-regulatory element. The construction method includes integrating an AAV element carrying an exogenous target gene and a polynucleotide that encodes the IE protein into to a baculovirus vector backbone. The obtained recombinant adeno-associated virus (rAAV) has a low empty capsid rate, while the rAAV yield of a single cell and a unit volume culture is increased, the production cost is reduced, and the production is easy to scale up.